Progenics and Wyeth Announce FDA Has Approved RELISTOR

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) and Wyeth Pharmaceuticals, a division of Wy...  More »

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR™ (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.  « Less